Sinonasal Lymphoepithelial Carcinoma With Aggressive Orbital Invasion

Srubarmaniam S, Ngoo Q, Wan Hitam W, et al. (November 04, 2022) Sinonasal Lymphoepithelial Carcinoma With Aggressive Orbital Invasion. Cureus 14(11): e31103. DOI 10.7759/cureus.31103

Abstract

Sinonasal lymphoepithelial carcinoma (LEC) is an extremely rare malignancy that shares some characteristics with nasopharyngeal carcinoma. In Asian populations, Epstein-Barr virus has been reported to be associated with LEC located outside of the nasopharynx. We report a rare case of sinonasal LEC with locoregional extension (brain and orbit). A 39-year-old Malay male initially presented with profound blurring of vision on the left eye (LE) and proptosis, followed by nasal symptoms of anosmia. Clinical examination revealed that the LE visual acuity was 6/36, with reduced optic nerve function with normal funduscopic findings, non-axial proptosis, and minimal limitation of extraocular movement. Subsequently, his vision worsened with perception of light in three days. Radioimaging studies showed soft tissue lesion at the ethmoid sinus with extensive local and intracranial extension. Microscopic analysis and immunohistochemistry confirmed the diagnosis of LEC. The patient was given induction chemotherapy followed by concurrent chemoradiotherapy with weekly intravenous cisplatin. Upon completing the fourth cycle of chemotherapy, the patient’s ocular symptoms and general conditions worsened. Repeated imaging showed worsening intracranial extension with cerebral and cerebellar edema, and the patient succumbed to death. Sinonasal LEC is a rare malignant tumor with little mention in the literature. This case was reported to highlight the importance of a high index of suspicion for acute ocular symptoms with mass.

Keywords:
proptosis, epstein-barr virus, ophthalmology, acute blindness, orbital, sinonasal tumor, lymphoepithelial carcinoma

Introduction

The occurrence of malignant tumors of the paranasal sinus is uncommon [1]. Lymphoepithelial carcinoma (LEC) tends to be located in various sites in the head and neck; however, sinonasal involvement, especially in the ethmoid sinus, is extremely rare. According to the World Health Organization, sinonasal LEC is defined as “poorly differentiated squamous cell carcinoma and morphologically similar to nasopharyngeal carcinoma” with a strong association with Epstein-Barr virus (EBV) [2]. In most cases, sinonasal LEC presents with locally aggressive disease with or without regional lymph node metastases. It is found to be more common in Southeast Asia [3]. We report a rare case of LEC in the ethmoid sinus invading the orbit and brain, which initially presented with loss of vision and proptosis.

Case Presentation

A 39-year-old Malay male with underlying allergic rhinitis presented to the ophthalmology clinic with unilateral, painless progressive loss of vision for one week and proptosis for two months. The patient also had a history of recurrent headaches averaging one to two times per week for the past three months. He was a heavy smoker but then switched to e-cigarette (“vaping”) two years ago. There was no history of appetite loss or weight loss. Visual acuity on presentation was 6/36 in the left eye (LE) and 6/6 in the right eye (RE). There was a presence of relative afferent pupillary defect (RAPD) grade 2 in the LE with reduced red desaturation and light brightness. Both anterior segments were unremarkable. Funduscopic examination revealed the LE visual acuity was 6/36, with reduced optic nerve function with normal funduscopic findings, non-axial proptosis, and minimal limitation of extraocular movement. Subsequently, his vision worsened with perception of light in three days. Radioimaging studies showed soft tissue lesion at the ethmoid sinus with extensive local and intracranial extension. Microscopic analysis and immunohistochemistry confirmed the diagnosis of LEC. The patient was given induction chemotherapy followed by concurrent chemoradiotherapy with weekly intravenous cisplatin. Upon completing the fourth cycle of chemotherapy, the patient’s ocular symptoms and general conditions worsened. Repeated imaging showed worsening intracranial extension with cerebral and cerebellar edema, and the patient succumbed to death. Sinonasal LEC is a rare malignant tumor with little mention in the literature. This case was reported to highlight the importance of a high index of suspicion for acute ocular symptoms with mass.
A contrasted-enhanced computed tomography (CECT) scan of the orbit, brain, and paranasal sinus (Figure 2) revealed an aggressive soft tissue lesion measuring 5.6 x 3.4 x 4.6 cm at the ethmoid sinus. There was an extensive local extension of the frontal sinus and maxillary sinus with bony destruction toward the frontal bone up to the pterygopalatine fossa. There was also intracranial extension (anterior cranial fossa) and in the orbital region toward the left extraconal stretching medial rectus, abutting the intracanalicular part of the optic nerve.

Biopsy of the mass revealed LEC. Immunohistochemistry showed tumor cells that were positive for pancytokeratin (pan-CK), cytokeratin CK5/6, and p63 gene with approximately 50% Ki-67 proliferation index, and negative for Epstein Barr encoding region in situ hybridization (EBER ISH). A diagnosis of sinonasal LEC with locoregional extension (brain and orbit) was made. The LE visual acuity of the patient vision deteriorated further to perception of light within a few days of admission. The LE proptosis became more prominent with the limitation of eye movement. The patient also had a nasal obstruction and anosmia (Figure 1B), but the RE remained normal. The patient was planned for induction chemotherapy of intravenous carboplatin and paclitexal 200 mg/m$^2$ followed by concurrent chemoradiotherapy (CCRT) with a dose of 70 Gy for 35 cycles for seven weeks and weekly intravenous cisplatin 40 mg/m$^2$. However, after completing the fourth cycle of chemotherapy, the patient developed headaches, seizures, and altered consciousness. Repeated CECT shows worsening intracranial extension with the involvement of the optic nerve. There was also the presence of diffuse cerebral and cerebellar edema. Subsequently, the patient succumbed to death after a few days.
Discussion

Sinonasal malignant neoplasm accounts for 0.1% of all neoplasms and 60% involving the maxillary sinus. It has a strong predilection for males, with a ratio of approximately 3:1 in the fifth to seventh decade of life [4]. Sinonasal LEC is rare, and around 40 documented cases have been reported so far [5]. LEC typically affects the nasopharynx, salivary glands, and larynx in the head and neck region [6]. In this case, the LEC originates from the ethmoid sinus, which is exceedingly rare in the literature. Over the years, numerous terms have been used to describe LEC in extrapharyngeal sites, such as lymphoepithelioma, lymphoepithelial-like carcinoma, lymphoepithelial-like carcinoma, undifferentiated carcinoma of nasopharyngeal type, and undifferentiated carcinoma with lymphoid stroma. Recently, it was accepted as a distinct entity separate from nasopharyngeal carcinoma (NPC) by topography and clinical outcome but histopathologically similar [7]. A study conducted in China shows the ratio of LEC to NPC to be 1:564 [8]. With a higher incidence rate of sinonasal LEC in Southeast Asian countries where ethnicity and geographical factors play a significant role, there is also an association with certain human leukocyte antigen (HLA) types, the southern Chinese diet, and EBV [6]. Around 90% of LEC cases are strongly associated with EBV. EBER ISH is the methodology of choice, which yields high sensitivity of detection for EBV [7]. In our patient, it tested negative for EBV. Nevertheless, inconsistent association between EBV and LEC has been observed in different races, such as in the USA and Western Europe, which are usually negative [9]. The status of EBV in the LEC of the maxillary sinus has no importance in prognostic value [10]. However, the treatment response and survival rate for the association of this virus and LEC have not been determined [1].

The signs and symptoms differ depending on the type, location, and stage of the malignancy [11]. The occurrence rate of sinonasal LEC is higher at the nasal cavity compared to paranasal sinuses. Commonly, patients present with nasal obstruction, epistaxis, and facial pain. Tumor invasion into the olfactory bulb, frontal lobe, and possibly brain stem causes anosmia and aguesia, whereas orbital invasion can lead to proptosis and cranial nerve palsies [5]. Symptoms such as epiphora, blood-tinged tears, and epistaxis were reported in a rare case of LEC of the nasoalcarinal duct [12]. In a comparison between sinonasal LEC and nasopharyngeal LEC, the frequency of cervical lymph node metastasis was smaller in the former, reported at around 15%. Orbital and intracranial invasions were seen in 31% and 15% cases, respectively [13]. In our case, the patient presented with ocular signs and symptoms prior to nasal symptoms. LEC from the maxillary sinus can be an aggressive tumor with local invasions to nerves and orbit [9]. Smoking is not a risk factor for LEC in nasopharyngeal sites [14]. However, the association between sinonasal LEC and smoking is yet to be established. In our case, the patient was a heavy smoker and switched to e-cigarettes. A study on e-cigarettes and nasal epithelial cells shows changes in the Ki-67 positive cells and pro-inflammatory CK [15]. Differential diagnoses for LEC include melanoma, lymphoma, and sinonasal undifferentiated carcinoma (SNUC). SNUC, which comes as a diagnosis of exclusion, is highly regarded as an aggressive tumor. Compared to LEC, microscopically, SNUC demonstrates high mitotic activity and necrosis with no association with EBV [3].

On standard radiography, sinonasal LEC shows a diffuse opacity of soft tissue density. CT scan of paranasal sinus shows a homogenous mass occupying the sinus cavity, which does not enhance even with contrast. The LEC cannot be distinguished from other sinonasal malignancies, particularly squamous cell carcinomas or lymphomas, and all these tumors are locally invasive with characteristics to metastasize to retropharyngeal and cervical node [9]. In terms of LEC definitive diagnosis, histopathological and immunohistochemistry analysis are warranted [11]. Microscopically, LEC is surrounded by poorly differentiated malignant epithelial cells with prominent infiltration of lymphocytes and plasma cells of the stroma [16]. In this case, immunohistochemical staining shows positive for pan-CK, indicating it is epithelial in nature with squamous differentiation from CK 5/6. There was a strong positivity for the proliferative marker Ki-67. The tumor cells are immunoreactive for the p63 gene, which highly signifies squamous cell carcinoma. In half of LEC cases, 10-75% of the tumors consist of squamous cell carcinoma components [17].

There is no standard treatment guideline for sinonasal LEC due to the rarity of this tumor and its anatomical complexity with close proximity to vital structures [3]. Initially, surgery is the treatment of choice; however, radiotherapy should be considered even if there is involvement of lymph nodes because LEC is radiosensitive [9]. Chemotherapy is recommended for non-nasopharyngeal LEC patients with regional adenopathy. These patients are at high risk of distant metastasis [2]. It can be given as neoadjuvant, concurrent, or adjuvant to radiotherapy [9]. A few studies stated the treatment of choice based on advanced NPC in view of similarities of LEC and NPC. In Japan, alternating chemoradiotherapy is given as a treatment choice for locoregional advanced NPC to minimize toxicity. The regime consists of three courses of chemotherapy (5-fluorouracil and cisplatin) and two courses of radiotherapy. Higher survival rates and lower toxicities are seen compared to CCRT. This method is suggested for sinonasal LEC in view of the high curative effect and better quality of life [2]. Another study administered chemotherapy of docetaxel plus carboplatin [1]. A long-term CT scan follow-up is necessary for maxillary sinus LEC since the recurrence rate is as high as 25% [6]. Sinonasal LEC has a five-year survival rate of around 50% [2]. The mortality rate per 1,000 patients is higher in Asian/Pacific Islander population, followed by African American/Black [16]. Our patient had cerebral and cerebellar edema while ongoing CCRT, and he died 10 weeks after the initial presentation.

Conclusions

2022 Suparmaniam et al. Cureus 14(11): e31103. DOI 10.7759/cureus.31103
In summary, we reported a case of an aggressive tumor of EBV-negative sinonasal LEC with locoregional extension (brain and orbit) that initially presented to us with ocular signs and symptoms. Due to LEC's rarity, diagnosis is based on histopathological examination with immunohistochemical studies, but definitive therapy is still not established. Our case report reminds us of the need to bear in mind that a harmless appearing swelling combined with ocular complaints could be a rare malignancy. This rare and challenging tumor needs a systematic clinical approach with vigilance, proper diagnostic tests, and appropriate treatment. A high index of suspicion among clinicians for early recognition and timely referral with further studies to guide appropriate management is required for the betterment of patients.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Jung H, Park SK, Heo KW, Kang MS: Lymphoepithelial carcinoma of the maxillary sinus with orbital invasion. Auris Nasus Larynx. 2009, 36:487-90. 10.1016/j.anl.2008.10.013
2. Takakura H, Tachino H, Fujisaka M, Nakajima T, Yamagishi K, Ishida M, Shojaku H: Lymphoepithelial carcinoma of the maxillary sinus: a case report and review of the literature. Medicine (Baltimore). 2018, 97:e11371. 10.1097/MD.0000000000011371
3. Bonnerup S, Gitas M, Shafigue K: A rare case of sinonasal lymphoepithelial carcinoma presented with clinically stage IV disease. Ear Nose Throat J. 2022, 101:586-91. 10.1177/0145561320955125
4. Thompson LDR: Sinonasal carcinomas. Curr Diagnostic Pathol. 2006, 12:40-53. 10.1016/j.cdip.2005.10.009
5. Guilmette J, Sadov PM: High-grade sinonasal carcinoma: classification through molecular profiling. Arch Pathol Lab Med. 2019, 143:1416-9. 10.5838/arpa.2018-0224-RS
6. Muthayam SR, Rauthuk R, Puhanpanthu K, Singh KT, Raj V, Kumar B: Lymphoepithelial carcinoma arising from the maxillary antrum: a clinicopathological report of a rare lesion in an unusual site. Quant Imaging Med Surg. 2014, 4:512-5. 10.3978/j.issn.2223-4292.2014.07.01
7. Emfietzoglou R, Pettas E, Georgaki M, et al.: Lymphoepithelial subtype of oral squamous cell carcinoma: report of an EBV-negative case and literature review. Dent J (Basel). 2022, 10:165. 10.3390/d10090165
8. Rytkönen AE, Hirvikoski PP, Salo TA: Lymphoepithelial carcinoma: two case reports and a systematic review of oral and sinonasal cases. Head Neck Pathol. 2011, 5:327-34. 10.1007/s12105-011-0278-7
9. Mohammed D, Jaber A, Philippe M, Kishore S: Lymphoepithelial carcinoma in the maxillary sinus: a case report. J Med Case Rep. 2012, 6:416. 10.1186/1752-1947-6-416
10. Iezzoni JC, Gaffey MJ, Weiss LM: The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol. 1995, 105:308-15. 10.1095/ajcp.105.3.308
11. Mahawar R, Devi YS: Lymphoepithelial carcinoma of the maxillary sinus: A case report. Indian J Case Reports. 2022, 8:154-6. 10.32677/ijcr.v8i5.3439
12. Tam YY, Lee LY, Chang KP: Lymphoepithelial carcinoma of the nasolacrimal duct. Otolaryngol Head Neck Surg. 2010, 142:144-5. 10.1016/j.ot攀登.2009.05.035
13. Zong Y, Liu K, Zhong B, Chen G, Wu W: Epstein-Barr virus infection of sinonasal lymphoepithelial carcinoma in Guangzhou. Chin Med J (Engl). 2001, 114:132-6.
14. Monteiro F, Baldaia H, Ribeiro L, et al.: Epstein-Barr virus-associated with lymphoepithelial carcinoma: a rare tumor of the larynx. Clin Med Insights Ear Nose Throat. 2019, 12:11795061986551. 10.1177/17955061986551
15. Rouabhia M, Piché M, Corriveau MN, Chakir J: Effect of e-cigarettes on nasal epithelial cell growth, Ki67 expression, and pro-inflammatory cytokine secretion. Am J Otolaryngol. 2020, 41:102686. 10.1016/j.amjoto.2020.102686
16. Picon H, Guddati AK: Analysis of trends in mortality in patients with lymphoepithelial carcinoma of the head and neck. Int J Gen Med. 2021, 14:6245-50. 10.2147/IJGM.S299145
17. Hammas N, Benmansour N, El Alami El Amine MN, Chbani L, El Fatemi H: Lymphoepithelial carcinoma: a case report of a rare tumor of the larynx. BMC Clin Pathol. 2017, 17:24. 10.1186/s12907-017-0061-0